Loading...

Zafgen

DB:ZA7
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ZA7
DB
$97M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and liver diseases. The last earnings update was 37 days ago. More info.


Add to Portfolio Compare Print
  • Zafgen has significant price volatility in the past 3 months.
ZA7 Share Price and Events
7 Day Returns
-0.8%
DB:ZA7
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-57.2%
DB:ZA7
-10.2%
DE Biotechs
-6%
DE Market
ZA7 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Zafgen (ZA7) -0.8% -9.1% -42.9% -57.2% -61.9% -
DE Biotechs -2.4% 1.8% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.2% 7.4% -6% 10.1% 15.4%
1 Year Return vs Industry and Market
  • ZA7 underperformed the Biotechs industry which returned -10.2% over the past year.
  • ZA7 underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
ZA7
Industry
5yr Volatility vs Market
Related Companies

ZA7 Value

 Is Zafgen undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Zafgen. This is due to cash flow or dividend data being unavailable. The share price is €2.335.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Zafgen's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Zafgen's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:ZA7 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.90
NasdaqGS:ZFGN Share Price ** NasdaqGS (2019-04-18) in USD $2.59
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Zafgen.

DB:ZA7 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ZFGN Share Price ÷ EPS (both in USD)

= 2.59 ÷ -1.90

-1.36x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Zafgen is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Zafgen is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Zafgen's expected growth come at a high price?
Raw Data
DB:ZA7 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.36x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
-9.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Zafgen, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Zafgen's assets?
Raw Data
DB:ZA7 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $2.50
NasdaqGS:ZFGN Share Price * NasdaqGS (2019-04-18) in USD $2.59
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.84x
DB:ZA7 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ZFGN Share Price ÷ Book Value per Share (both in USD)

= 2.59 ÷ 2.50

1.04x

* Primary Listing of Zafgen.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Zafgen is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Zafgen's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Zafgen has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ZA7 Future Performance

 How is Zafgen expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-9.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Zafgen expected to grow at an attractive rate?
  • Unable to compare Zafgen's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Zafgen's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Zafgen's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:ZA7 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:ZA7 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts -9.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:ZA7 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:ZA7 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 0 -75 -97 2
2022-12-31 0 -19 -91 2
2021-12-31 0 -66 -77 2
2020-12-31 3 -61 -71 4
2019-12-31 2 43 -61 5
DB:ZA7 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -51 -61
2018-09-30 -49 -60
2018-06-30 -49 -57
2018-03-31 -45 -55
2017-12-31 -44 -52
2017-09-30 -43 -49
2017-06-30 -42 -51
2017-03-31 -46 -53
2016-12-31 -52 -58
2016-09-30 -61 -71
2016-06-30 -66 -76
2016-03-31 -66 -79

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Zafgen is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Zafgen is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:ZA7 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Zafgen Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:ZA7 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -1.55 -1.55 -1.55 1.00
2022-12-31 -1.43 -1.43 -1.43 1.00
2021-12-31 -1.31 -1.31 -1.31 1.00
2020-12-31 -1.71 -1.15 -2.34 3.00
2019-12-31 -1.74 -1.31 -2.21 5.00
DB:ZA7 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.90
2018-09-30 -2.01
2018-06-30 -2.09
2018-03-31 -2.00
2017-12-31 -1.90
2017-09-30 -1.80
2017-06-30 -1.88
2017-03-31 -1.95
2016-12-31 -2.12
2016-09-30 -2.59
2016-06-30 -2.78
2016-03-31 -2.89

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Zafgen will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Zafgen's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Zafgen has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ZA7 Past Performance

  How has Zafgen performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Zafgen's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Zafgen does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Zafgen's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Zafgen's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Zafgen's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Zafgen Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:ZA7 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -61.37 13.19 47.93
2018-09-30 -59.88 12.41 47.38
2018-06-30 -57.40 12.18 45.28
2018-03-31 -54.97 11.84 43.60
2017-12-31 -52.03 12.16 40.84
2017-09-30 -49.38 11.97 36.74
2017-06-30 -51.47 13.69 37.02
2017-03-31 -53.15 15.58 36.65
2016-12-31 -57.88 17.35 39.47
2016-09-30 -70.61 20.63 50.37
2016-06-30 -75.82 21.35 54.54
2016-03-31 -78.55 21.53 56.90
2015-12-31 -74.29 19.20 54.62
2015-09-30 -62.04 16.97 44.26
2015-06-30 -56.85 13.71 42.16
2015-03-31 -45.54 9.92 34.33
2014-12-31 -36.57 8.14 27.39
2014-09-30 -29.54 6.06 22.57
2014-06-30 -18.41 4.86 12.94
2014-03-31 -15.15 4.58 10.20
2013-12-31 -14.24 4.22 9.56
2013-09-30 -13.43 3.58 9.44
2012-12-31 -13.95 2.25 11.54

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Zafgen has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Zafgen has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Zafgen improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Zafgen's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Zafgen has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ZA7 Health

 How is Zafgen's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Zafgen's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Zafgen is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Zafgen's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Zafgen's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 5.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Zafgen Company Filings, last reported 3 months ago.

DB:ZA7 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 93.27 20.64 118.07
2018-09-30 103.94 20.48 127.83
2018-06-30 52.02 20.32 75.85
2018-03-31 65.00 20.16 89.07
2017-12-31 78.22 20.00 102.05
2017-09-30 89.23 1.27 93.18
2017-06-30 99.63 2.06 105.99
2017-03-31 110.77 2.84 116.94
2016-12-31 121.73 3.59 129.19
2016-09-30 130.17 4.32 138.66
2016-06-30 142.24 5.03 150.47
2016-03-31 154.43 5.72 166.18
2015-12-31 169.11 6.39 185.08
2015-09-30 189.70 7.04 203.95
2015-06-30 206.19 7.67 220.12
2015-03-31 221.67 7.61 234.20
2014-12-31 104.44 7.56 115.46
2014-09-30 111.20 7.50 127.03
2014-06-30 125.42 7.45 134.23
2014-03-31 31.38 7.38 38.48
2013-12-31 35.22 0.00 35.52
2013-09-30 4.08 0.00 4.85
2012-12-31 8.06 0.00 9.94
  • Zafgen's level of debt (22.1%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0.2% vs 22.1% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Zafgen has sufficient cash runway for 2.3 years based on current free cash flow.
  • Zafgen has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of -12.1% each year.
X
Financial health checks
We assess Zafgen's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Zafgen has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ZA7 Dividends

 What is Zafgen's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Zafgen dividends.
If you bought €2,000 of Zafgen shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Zafgen's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Zafgen's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:ZA7 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:ZA7 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Zafgen has not reported any payouts.
  • Unable to verify if Zafgen's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Zafgen's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Zafgen has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Zafgen's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Zafgen afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Zafgen has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ZA7 Management

 What is the CEO of Zafgen's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jeff Hatfield
COMPENSATION $4,529,387
AGE 60
TENURE AS CEO 1.5 years
CEO Bio

Mr. Jeffrey S. Hatfield, also known as Jeff, has been the Chief Executive Officer and Director at Zafgan, Inc. since October 10, 2017. Mr. Hatfield is an Atlas Advisor of Atlas Venture L.P. He is a Veteran biotechnology and pharmaceutical industry leader, with over three decades of experience. He was an Entrepreneur-in-Residence, Venture Partner and Advisor at the Atlas Venture L.P. He served as the Chief Executive Officer and President of Vitae Pharmaceuticals, Inc. from March 2004 to September 25, 2016. He has relevant industry experience. He has over 30 years of experience in the biopharmaceutical industry. He was nearly twenty years with Bristol-Myers Squibb Company which he joined in 1985 and served as Senior Vice President of Immunology and Virology Divisions from 2000 to 2004. His career also included responsibilities as President and General Manager of BMS-Canada from 1997 to 2000, Vice President of U.S. Managed Health Care for BMS from 1996 to 1997, Vice President of US Market Access and a variety of marketing, sales and general management positions. At BMS, he was directly associated with several product successes, including Pravachol®, Plavix®, Glucophage©, Avapro®, Abilify®, Reyataz®, and Atripla®. He was responsible for sales, marketing, policy and medical strategy within the HIV, hepatitis and RA therapeutic categories. He has been a Director of Miragen Therapeutics, Inc. since August 10, 2017 and also serves as its Chairman of the Board since December 5, 2018. He has been an Independent Director of aTyr Pharma, Inc. since April 03, 2017. He was Director at InVivo Therapeutics Holdings Corp. from November 2, 2016 to December 31, 2018. He serves as a Director of the Biotechnology Industry Organization (BIO). He is a Dean’s Advisory Council Member for Purdue University’s College of Pharmacy. He served as a Director of Vitae Pharmaceuticals, Inc. from March 2004 to September 2016. He served on the board of Ambit Therapeutics, Inc. He served as a Director of Ambit Biosciences Corporation from June 4, 2014 to November 10, 2014. He was an Adjunct Professor at Purdue University. Mr. Hatfield is on faculty of Drexel University's LeBow College of Business and the Chapman-KGI School of BioPharmacy. He holds Bachelor of Science Degree in Pharmacy from Purdue University's School of Pharmacy and a Master of Business Administration degree from the Wharton School at the University of Pennsylvania.

CEO Compensation
  • Insufficient data for Jeff to compare compensation growth.
  • Jeff's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Zafgen management team in years:

3.9
Average Tenure
56
Average Age
  • The tenure for the Zafgen management team is about average.
Management Team

Jeff Hatfield

TITLE
CEO & Director
COMPENSATION
$5M
AGE
60
TENURE
1.5 yrs

Patricia Allen

TITLE
Chief Financial Officer
COMPENSATION
$705K
AGE
56
TENURE
6.3 yrs

Dennis Kim

TITLE
Chief Medical Officer
COMPENSATION
$786K
AGE
48
TENURE
7.6 yrs

James Vath

TITLE
Head of Discovery & Development
AGE
57
TENURE
13.3 yrs

Brian McVeigh

TITLE
Chief Business Officer
AGE
45
TENURE
0.9 yrs

Priya Singhal

TITLE
Head of Research & Development
TENURE
0.1 yrs
Board of Directors Tenure

Average tenure and age of the Zafgen board of directors in years:

4
Average Tenure
62
Average Age
  • The tenure for the Zafgen board of directors is about average.
Board of Directors

Peter Barrett

TITLE
Chairman of the Board
COMPENSATION
$116K
AGE
65
TENURE
12.7 yrs

Jeff Hatfield

TITLE
CEO & Director
COMPENSATION
$5M
AGE
60
TENURE
1.5 yrs

Frank Thomas

TITLE
Independent Director
COMPENSATION
$94K
AGE
48
TENURE
4.8 yrs

Tom Daniel

TITLE
Independent Director
COMPENSATION
$89K
AGE
64
TENURE
3.1 yrs

Tom Hughes

TITLE
Member of Scientific Advisory Board
COMPENSATION
$2M
AGE
58
TENURE
0.7 yrs

Randy Seeley

TITLE
Member of Clinical Advisory Board

Steve Smith

TITLE
Member of Clinical Advisory Board

Louis Aronne

TITLE
Member of Clinical Advisory Board
AGE
62

John LaMattina

TITLE
Independent Director
COMPENSATION
$91K
AGE
68
TENURE
5.3 yrs

Caroline Apovian

TITLE
Member of Clinical Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Zafgen's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Zafgen has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ZA7 News

Simply Wall St News

ZA7 Company Info

Description

Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and liver diseases. Its lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase II clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. The company also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS; and ZGN-1345, an orally dosed MetAP2 inhibitor specifically targeting the liver. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.

Details
Name: Zafgen, Inc.
ZA7
Exchange: DB
Founded: 2005
$85,937,761
37,315,118
Website: http://www.zafgen.com
Address: Zafgen, Inc.
1-3 Center Plaza,
Boston,
Massachusetts, United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ZFGN Common Stock Nasdaq Global Select US USD 20. Jun 2014
DB ZA7 Common Stock Deutsche Boerse AG DE EUR 20. Jun 2014
Number of employees
Current staff
Staff numbers
38
Zafgen employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/20 21:44
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/13
Last earnings filing: 2019/03/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.